Ipamorelin 10mg
99.3% HPLC PurityResearch-grade Ipamorelin 10mg lyophilised powder. 99.3% HPLC purity, COA verified. Selective growth-hormone secretagogue (GHRP) for research.

SKU: PW-017 • Batch: PW-260713
Research-grade Tesamorelin 10mg lyophilised powder. 99.1% HPLC purity, COA verified. Stabilised GHRH analogue for growth-hormone research.
Read the full description ↓✓Free shipping on orders over $750 AUD
✓Tracked international post — Standard $39.99 / Express $69.99 AUD
✓Dispatched next business day (orders before 11PM AEST)
Research-grade Ipamorelin 10mg lyophilised powder. 99.3% HPLC purity, COA verified. Selective growth-hormone secretagogue (GHRP) for research.
Purity independently verified by an accredited third-party laboratory via HPLC & mass spectrometry.
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH 1-44) modified with a trans-3-hexenoic acid group for increased stability. Supplied as a lyophilised powder at 99.1% HPLC purity with full Certificate of Analysis (COA) documentation.
Our Tesamorelin is sourced from GMP-certified manufacturing facilities with full chain-of-custody documentation maintained from synthesis to our Australian labs. Every batch undergoes independent third-party HPLC testing, mass spectrometry identity confirmation, LAL endotoxin assay (<1.0 EU/mg), and sterility screening before dispatch.
Research has explored Tesamorelin's GHRH-receptor agonist activity and its effects on the GH/IGF-1 axis in metabolic research models. Strictly for in-vitro laboratory research only.
Tesamorelin is a stabilised GHRH analogue studied in preclinical research for its GHRH-receptor agonist activity and effects on the GH/IGF-1 axis. All use is strictly for in-vitro laboratory research only.
Our Tesamorelin 10mg is independently verified at 99.1% HPLC purity. Each batch is tested by an accredited third-party laboratory and ships with a full Certificate of Analysis (COA).
Store lyophilised at −20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.
Add bacteriostatic water (BAC water) slowly to the vial at a 1–2mL volume. Gently swirl; do not shake. Allow the powder to dissolve completely before use in research protocols.
Tesamorelin 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable laws and regulations.
No questions yet — be the first to ask about this product.
Synergistic blend of CJC-1295 (GHRH analogue) and Ipamorelin (GHRP) studied for amplified GH release, body composition, and recovery research.
Research-grade Retatrutide 10mg lyophilised powder. 99.4% HPLC purity, COA verified. Triple GLP-1/GIP/Glucagon receptor agonist for metabolic research.
Recent peer-reviewed studies from PubMed related to Tesamorelin. Provided for research context — not medical advice.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Russo SC, Ockene MW, Arpante AK, et al. · AIDS (London, England) · 2024
PMID: 38905488
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Badran AS, Helal A, Shata KS, et al. · Obesity research & clinical practice · 2026
PMID: 41545261
Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S, Gavrilović I, Ng K, et al. · Drug testing and analysis · 2021
PMID: 34665524
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz J, Mamputu JC, Potvin D, et al. · The Journal of clinical endocrinology and metabolism · 2010
PMID: 20554713
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.